Advertisement

Topics

Samsung Bioepis to Initiate Phase 1 Clinical Trial of SB26 Ulinastatin-Fc Fusion Protein

19:00 EDT 12 Aug 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
SB26, also known as TAK-671, is intended to treat severe acute pancreatitis SB26 is the first therapeutic candidate in the risk-sharing strategic collaboration agreement between Samsung Bioepis and Ta...

Other Sources for this Article

Samsung Bioepis Co., Ltd.
MEDIA
Mingi Hyun
+82-31-8061-1594
mingi.hyun@samsung.com

NEXT ARTICLE

More From BioPortfolio on "Samsung Bioepis to Initiate Phase 1 Clinical Trial of SB26 Ulinastatin-Fc Fusion Protein"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...